b±se (95% CI) | n | p-value | |
Baseline sleep parameters | |||
TST min | 0±0.002 (−0.005–0.005) | 1805 | 0.971 |
Sleep efficiency % | 0.002±0.003 (−0.003–0.01) | 1805 | 0.543 |
N3 sleep % | −0.005±0.006 (−0.018–0.007) | 1805 | 0.454 |
REM sleep % | 0.001±0.04 (−0.007–0.007) | 1805 | 0.879 |
Arousal index events·h−1 | 0.001±0.018 (−0.034–0.037) | 1805 | 0.938 |
Mean SpO2 % | 0.004±0.012 (−0.002–0.034) | 1805 | 0.304 |
Lowest SpO2 % | 0.004±0.015 (−0.027–0.033) | 1805 | 0.762 |
3% ODI events·h−1 | 0.005±0.039 (−0.067–0.089) | 1802 | 0.887 |
Time with SpO2 <90% % | 0.018±0.006 (0.008–0.033) | 1784 | 0.008 |
Follow-up cardiometabolic parameters | |||
Waist circumference cm | 0.072±0.022 (0.029–0.118) | 1805 | 0.002 |
SBP mmHg | 0.021±0.016 (−0.014–0.053) | 1802 | 0.207 |
DBP mmHg | 0.006±0.016 (−0.028–0.037) | 1805 | 0.748 |
Total cholesterol mmol·L−1 | −0.006±0.006 (−0.019–0.004) | 1805 | 0.31 |
HDL cholesterol mmol·L−1 | 0.009±0.013 (−0.016–0.034) | 1805 | 0.45 |
LDL cholesterol mmol·L−1 | −0.006±0.005 (−0.018–0.002) | 1798 | 0.243 |
Triglycerides mmol·L−1 | 0.013±0.022 (−0.023–0.066) | 1805 | 0.447 |
Fasting glucose mmol·L−1 | 0.037±0.02 (0–0.076) | 1804 | 0.033 |
Fasting insulin pmol·L−1 | 0.05±0.016 (0.020–0.081) | 1783 | 0.002 |
HOMA-IR | 0.053±0.016 (0.022–0.083) | 1781 | 0.001 |
hs-CRP nmol·L−1 | 0.006±0.005 (−0.001–0.022) | 1669 | 0.187 |
TST: total sleep time; N3: slow wave; REM: rapid eye movement; SpO2: arterial oxygen saturation measured by pulse oximetry; ODI: oxygen desaturation index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: homeostatic model assessment of insulin resistance; hs-CRP: high-sensitivity C-reactive protein. Data were analysed with mediation regressions using the PROCESS procedure for SPSS version 2.16.3 with adjustment for sex, age, cohort, body mass index and number of MetS components at baseline. Additional covariates for SBP and DBP (use of antihypertensive medication at baseline and follow-up); total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides (use of hypolipidaemic medication at baseline and follow-up); and fasting glucose, fasting insulin and HOMA-IR (use of antidiabetic medication at baseline and follow-up). For cardiometabolic parameters, each follow-up measure was additionally adjusted by its respective baseline measure. p<0.05 considered statistically significant.